A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 95,383 shares of YMAB stock, worth $1.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
95,383
Previous 358,945 73.43%
Holding current value
$1.06 Million
Previous $4.34 Million 71.13%
% of portfolio
0.0%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$9.95 - $15.39 $2.62 Million - $4.06 Million
-263,562 Reduced 73.43%
95,383 $1.25 Million
Q2 2024

Aug 14, 2024

SELL
$11.6 - $17.25 $13.6 Million - $20.2 Million
-1,168,155 Reduced 76.49%
358,945 $4.34 Million
Q1 2024

May 15, 2024

BUY
$6.57 - $18.69 $10 Million - $28.5 Million
1,527,100 New
1,527,100 $24.8 Million
Q3 2023

Nov 14, 2023

SELL
$4.86 - $7.23 $1.48 Million - $2.2 Million
-303,987 Reduced 79.25%
79,600 $433,000
Q2 2023

Aug 14, 2023

BUY
$5.68 - $10.34 $149,775 - $272,655
26,369 Added 7.38%
383,587 $2.6 Million
Q1 2023

May 15, 2023

SELL
$2.83 - $5.11 $260,959 - $471,203
-92,212 Reduced 20.52%
357,218 $1.79 Million
Q4 2022

Feb 14, 2023

BUY
$3.0 - $15.17 $1.35 Million - $6.82 Million
449,430 New
449,430 $2.19 Million
Q3 2019

Nov 15, 2019

SELL
$21.57 - $31.37 $647,100 - $941,100
-30,000 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$19.51 - $28.31 $585,300 - $849,300
30,000 New
30,000 $686,000
Q4 2018

Feb 14, 2019

SELL
$15.41 - $28.92 $77,050 - $144,600
-5,000 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$24.0 - $26.97 $120,000 - $134,850
5,000 New
5,000 $133,000

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $487M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.